2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge, with adjust
强生2023年第一季度报告 Johnson Johnson Reports Q1 2023 Results.docx,FOR IMMEDIATE RELEASE ? 2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* ? 2023 First-Quarter
Get the detailed income statement for Johnson & Johnson (JNJ). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue.
Find the latest Johnson & Johnson Common Stock (JNJ) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.
New Brunswick, N.J. (September 29, 2023)–Johnson & Johnson(the “Company”) (NYSE: JNJ) today confirmed its intent not to enforce patents it owns and controls for SIRTURO® (bedaquiline) in the tr...
Johnson & Johnson, normally a defensive stock, has fallen more than the S&P 500 during this downturn.
Johnson & Johnson (JNJ.NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Johnson & Johnson | Nyse: JNJ | Nyse
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products and medical devices. The company conducts business through its operating companies. It provides pharmaceuticals for immune disorders, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases;...
Johnson & Johnson (NYSE: JNJ) Q3 2023 Earnings Call datedOct. 17, 2023 Corporate Participants: Jessica Moore—Vice President – Investor Relations Joseph J. Wolk—Executive Vice President, Chief Financial Officer Joaquin Duato—Chairman and Chief Executive Officer ...
Johnson & Johnson (JNJ.NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Johnson & Johnson | Nyse: JNJ | Nyse